FDAnews
www.fdanews.com/articles/96476-medivation-commences-treatment-in-phase-ii-trial-of-dimebon

Medivation Commences Treatment in Phase II Trial of Dimebon

July 30, 2007

Medivation announced the treatment of the first patient in its Phase II trial of Dimebon for Huntington’s disease.

Medivation said it has expanded patient enrollment in the trial by 20 percent — to 90 patients — to detect differences between Dimebon and placebo.

The randomized, placebo-controlled, double-blinded study will evaluate the safety and preliminary efficacy of Dimebon in 90 Huntington’s disease patients after three months of dosing, the company said.

The study will be conducted at approximately 17 sites in the U.S. and Europe, the company added.

The company said it expects to report study data in the first half of 2008.